Biodesix to present new molecular residual disease testing data at AMP 2026
BDSX•Biodesix will present molecular residual disease data at the Association for Molecular Pathology meeting in Seattle, Nov. 10-14, 2026. The work includes tumor-informed testing developed with Bio-Rad Laboratories and a tumor-naïve approach under development with Thermo Fisher Scientific.
1. Testing programs
Biodesix will present new molecular residual disease data at the Association for Molecular Pathology meeting in Seattle, Nov. 10-14, 2026. Its tumor-informed research uses blood-based monitoring of complex tumor alterations with assays developed with Bio-Rad Laboratories; a tumor-naïve approach under development with Thermo Fisher Scientific requires no tumor tissue and may expand access for patients with insufficient samples. Both programs are being validated with Memorial Sloan Kettering Cancer Center investigators, with deployment targeted on partner platforms already installed in laboratories.
